Роль COX-2 в регуляции метастатического потенциала опухолевых клеток молочной железы человека

Проведен анализ экспрессии СOX-2, VEGF, VEGFR-1, VEGFR-2, VEGFR-3, EGFR, эндоглина (СD105), IL-6 в опухолевых клетках молочной железы человека с разным метастатическим потенциалом. Исследовалась роль данных факторов в регуляции мета- статического потенциала клеток рака молочной железы, а также роль СOX-2 в регуляции процессов метастазирования на клеточном уровне; оценивалась потенциальная способность опухолевых клеток молочной железы человека вырабатывать фак- торы, стимулирующие рост опухоли, ангиогенез и метастазирование.

рак молочной железы, СOX-2, VEGF, VEGFR-2, VEGFR-3, EGFR, эндоглин (СD105), IL-6, ангиогенез, метаста- зирование, линии опухолевых клеток молочной железы человека MCF-7, BT-474, ZR-75-1, мишени для таргетной терапии

1. Curado M.P., Edwards B., Shin H.R. et al. Cancer Incidence in Five Continents. Vol. IX. IARC Scientific Publications. No.160. Lyon: IARC, 2007.

2. Schedin P., Borges V. Breaking down barriers: the importance of the stromal microenvironment in acquiring invasiveness in young women's breast cancer. Breast Cancer Res 2009;11(2):102.

3. Wang S., Chen C., Meng Y. et al. Effective suppression of breast tumor growth by an anti- EGFR/ErbB2 bispecific antibody. Cancer Lett 2012;325(2):214–9.

4. Song Y., Dai F., Zhai D. et al. Usnic acid inhibits breast tumor angiogenesis and growth by suppress- ing VEGFR2-mediated AKT and ERK1/2 signal- ing pathways. Angiogenesis 2012;15(3):421–32.

5. Zhao Y.C., Ni X.J., Wang M.H. et al. Tu- mor-derived VEGF-C, but not VEGF-D, promotes sentinel lymph node lymphangiogenesis prior to metastasis in breast cancer patients. Med Oncol 2012;29(4):2594–600.

6. Bayoudh L., Afrit M., Daldoul O. et al. Trastuzumab (herceptin) for the medical treat- ment of breast cancer. Tunis Med 2012;90(1):6–12.

7. Han S.W., Cha Y., Paquet A. et al. Correla- tion of HER2, p95HER2 and HER3 expres- sion and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer. PLoS One 2012;7(7):e39943.

8. Amiri-KordestaniL.,TanA.R.,SwainS.M. Pazopanib for the treatment of breast cancer. Expert Opin Investig Drugs 2012;21(2):217–25.

9. Perez E.A., Spano J.P. Current and emerg- ing targeted therapies for metastatic breast can- cer. Cancer 2012;118(12):3014–25.

10. Dai Y., Hogan S., Schmelz E.M. et al. Selective growth inhibition of human breast cancer cells by graviola fruit extract in vitro and in vivo involving downregulation of EGFR ex- pression. Nutr Cancer 2011;63(5):795–801.

11. Liu Z.B., Hou Y.F., Zhu J. et al. Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-de- pendent manner. Oncogene 2010;29(20):2996– 3009.

12. Kim S., Han J., Lee S.K. et al. Smad7 acts as a negative regulator of the epidermal growth factor (EGF) signaling pathway in breast can- cer cells. Cancer Lett 2012;314(2):147–54.

13. Tunca B., Egeli U., Cecener G. et al. CK19, CK20, EGFR and HER2 status of cir- culating tumor cells in patients with breast can- cer. Tumori 2012;98(2):243–51.

14. Runkle K.B., Meyerkord C.L., Desai N.V. et al. Bif-1 suppresses breast cancer cell migra- tion by promoting EGFR endocytic degrada- tion. Cancer Biol Ther 2012;13(10):956–66.

15. Jiang Q., Zhou C., Bi Z., Wan Y. EGF-in- duced cell migration is mediated by ERK and PI3K/AKT pathways in cultured human lens epithelial cells. J Ocul Pharmacol Ther 2006;22(2):93–102.

16. Ryan P.D., Goss P.E. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008;13(1):16–24.

17. Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79(4): 1193–226.

18. Araki K., Hashimoto K., Ardyanto T.D. Co-expression of Cox-2 and EGFR in stage I human bronchial adenocarcinomas. Lung Cancer 2004;45(2):161–9.

19. Ceccarelli C., Piazzi G., Paterini P. Concurrent EGFr and Cox-2 expression in colorectal cancer: proliferation impact and

20. tumour spreading. Ann Oncol 2005; 16(4):74–9.

21. Kang J.H., Song K.H., Jeong K.C. et al. Involvement of COX-2 in the metastatic poten- tial of chemotherapy-resistant breast cancer cells. BMC Cancer 2011;11:334.

22. Wang Y.X., Gao J.X., Wang X.Y. et al. Antiproliferative effects of selective cyclooxy- genase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells. Tumour Biol 2012;33(4):957–66.

23. Dannenberg A.J., Lippman S.M., Mann J.R. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005;23(2):254–66.

24. Kalous O., Conklin D., Desai A.J. et al. Dacomitinib (PF-00299804), a irreversible pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resis- tant to trastuzumab and lapatinib. Mol Cancer Ther 2012;11(9):1978–87.

25. Wagner A.D., Thomssen C., Haerting J., Unverzagt S. Vascular-endothelial-growth-fac- tor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev 2012;7:CD008941.

26. Cybulski M., Jarosz B., Nowakowski A.

27. et al. Cyclin I correlates with VEGFR-2 and cell proliferation in human epithelial ovarian cancer. Gynecol Oncol 2012;127(1):217–22.

28. Raica M., Cimpean A.M., Ceausu R., Ribatti D. Lymphatic microvessel density, VEGF-C, and VEGFR-3 expression in differ- ent molecular types of breast cancer. Anticancer Res 2011;31(5):1757–64.

29. Smith N.R., Baker D., James N.H. et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized pri- marily to the vasculature in human primary solid cancers. Clin Cancer Res 2010;16(14):3548–61.

30. Sarkar S., Mazumdar A., Dash R. et al. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther 2010;9(8):592–603.

31. Valtola R., Salven P., Heikkilä P. et al. VEGFR-3 and its ligand VEGF-C are associ- ated with angiogenesis in breast cancer. Am J Pathol 1999;154(5):1381–90.

32. KarroumA.,MirshahiP.,FaussatA.M. et al. Tubular network formation by adriamycin-re- sistant MCF-7 breast cancer cells is closely linked to MMP-9 and VEGFR-2/VEGFR-3 over-expres- sions. Eur J Pharmacol 2012;685(1–3):1–7.

33. Su J.L., Yen C.J., Chen P.S. et al. The role of the VEGF-C/VEGFR-3 axis in cancer pro- gression. Br J Cancer 2007;96(4):541–5.

34. Davidson B., Stavnes H.T., Førsund M. et al. CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival. Breast 2010;19(6):493–8.

35. Smith A.L., Iwanaga R., Drasin D.J. et al. The miR-106b-25 cluster targets Smad7, acti- vates TGF-β signaling, and induces EMT and tumor initiating cell characteristics down- stream of Six1 in human breast cancer. Onco- gene 2012;31(50):5162–71.

36. Reinholz M.M., An M.W., Johnsen S.A. et al. Differential gene expression of TGF beta inducible early gene (TIEG), Smad7, Smad2 and Bard1 in normal and malignant breast tis- sue. Breast Cancer Res Treat 2004;86(1):75–88.

37. Scollen S., Luccarini C., Baynes C. et al. TGF-β signaling pathway and breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2011;20(6):1112–9.

38. Oxmann D., Held-Feindt J., Stark A.M.

39. et al. Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype. Oncogene 2008;27(25):3567–75.

40. Lee S.H., Mizutani N., Mizutani M. et al. Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol Immunother 2006;55(12):1565–74.

41. Fonsatti E., Jekunen A.P., Kairemo K.J. et al. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 2000;6(5):2037–43.

42. Shi Z., Yang W.M., Chen L.P. et al. Enhanced chemosensitization in multidrug- resistant human breast cancer cells by inhibi- tion of IL-6 and IL-8 production. Breast Cancer Res Treat 2012;135(3):737–47.

43. Jehn C.F., Flath B., Strux A. et al. Influ- ence of age, performance status, cancer activ- ity, and IL-6 on anxiety and depression in pa- tients with metastatic breast cancer. Breast Cancer Res Treat 2012;136(3):789–94.

44. Marrogi A.J., Munshi A., Merogi A.J. et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prog- nostic factors in breast carcinoma. Int J Cancer 1997;74(5):492–501.

45. Knupfer H., Schmidt R., Stanitz D. et al. CYP2C and IL-6 expression in breast cancer. Breast 2004;13(1):28–34.

46. Ueno T., Toi M., Saji H. et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000;6(8):3282–9.

47. Bachelot T., Ray-Coquard I., Menetrier- Caux C. et al. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hor- mone-refractory metastatic breast cancer pa- tients. Br J Cancer 2003;88(11):1721–6.